• 검색 결과가 없습니다.

Next generation sequencing and urologic cancer

N/A
N/A
Protected

Academic year: 2021

Share "Next generation sequencing and urologic cancer"

Copied!
3
0
0

로드 중.... (전체 텍스트 보기)

전체 글

(1)

87 Nucleic acid sequencing is a method for identifying

the exact nucleotides present in a given DNA or RNA molecule. After completion of the first human genome sequence from the Human Genome Project by first- generation sequencing (also known as Sanger sequencing), the use of nucleic acid sequencing has greatly increased in research and clinical investigations worldwide, with a resultant demand for cheaper and faster sequencing methods. This demand has driven the development of next-generation sequencing (NGS), in which massively parallel sequencing is performed, which allows an entire genome to be sequenced from millions of fragments of DNA samples in less than 1 day. During the last decade, several NGS platforms, such as the Illumina HiSeq series, SOLiD, or 454, have been developed to provide low-cost and high-throughput sequencing. The creation of these NGS platforms has made sequencing accessible to more laboratories and has facilitated the discovery of genes and regulatory elements associated with diseases including urologic cancers.

The application of NGS has gradually broadened, allowing for rapid advances in many fields associated with the biomedical sciences and clinical research.

Whole-genome sequencing (also known as full-genome sequencing, complete genome sequencing, or entire genome sequencing) is a laboratory process that determines the complete DNA sequence of a sample's genome at a single

Next generation sequencing and urologic cancer

Seon-Kyu Kim, Wun-Jae Kim1

Medical Genomics Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 1Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Korean J Urol 2015;56:87-89.

http://dx.doi.org/10.4111/kju.2015.56.2.87 pISSN 2005-6737 • eISSN 2005-6745

Editorial

Corresponding Author: Wun-Jae Kim

Department of Urology, Chungbuk National University College of Medicine, 410 Sunbong-ro, Heungdeok-gu, Cheongju 361-763, Korea TEL: +82-43-269-6371, FAX: +82-43-269-6144, E-mail: wjkim@chungbuk.ac.kr

ⓒ The Korean Urological Association, 2015

time. This entails sequencing of chromosomal DNA as well as DNA contained in the mitochondria. In the fu- ture of personalized medicine, whole-genome sequence data will be an important tool for guiding therapeutic interventions. The tool of gene sequencing at the single- nucleotide polymorphism (SNP) level is also used to pinpoint functional DNA variants from association studies and may lay the foundation for predicting disease susceptibility and drug response. Additionally, gene expression studies using RNA-seq (also known as whole- transcriptome sequencing) have begun to replace the use of DNA microarray analysis, providing the ability to visualize RNA expression in sequence form. RNA-seq is an experimental protocol that uses NGS technologies to sequence the RNA molecules within a biological sample in an effort to determine the relative abundance of each RNA.

Although sequencing of the entire human genome by the whole-genome sequencing method is possible, researchers and clinicians are typically interested in only the protein-coding regions of the genome, which is referred to as the exome. The exome makes up just over 1% of the genome. Thus, whole-exome sequencing is much more cost- effective than whole-genome sequencing, because exome sequencing can provide sequence information for protein- coding regions.

These are simply some of the broad applications that

www.kjurology.org

(2)

88 www.kjurology.org http://dx.doi.org/10.4111/kju.2015.56.2.87

Kim and Kim

skim the surface of what NGS can offer to translational researchers and clinicians. As NGS continues to grow in popularity, it is inevitable that there will be additional innovative applications.

NGS is uncovering human genome diversity at both the germ-line level (population) and the somatic level (tumors).

Several cooperative groups such as the International Cancer Genome Consortium and The Cancer Genome Atlas (TCGA) Research Network provide platforms for effective worldwide collaboration in various cancers. Since 2010, whole-genome and whole-exome sequencing data of urological cancers, including kidney cancer, bladder cancer, and prostate cancer (PCa), have become available to the research community. Studies from the Wellcome Trust have shown a high frequency of inactivation of polybromo 1 (PBRM1) in 40% of renal cell carcinomas (RCCs) and recurrent mutations in genes involved in histone methylation: SET domain containing 2 (SETD2), lysine (K)- specific demethylase 5C (KDM5C), and lysine (K)-specific demethylase 6A (KDM6A) [1]. BRCA1-associated protein-1 (BAP1) was found inactivated in 15% of RCCs [2]. PBRM1 and BAP1 mutations are generally exclusive [3], which was confirmed by the TCGA study. SETD2-associated DNA methylation subsets were identified by TCGA, which provided evidence demonstrating that multiple RNA- based tumor subtypes are characterized by mutations in PBRM1 and the mechanistic target of BAP1 [4]. In bladder cancer, whole-exome sequencing has revealed mutations in chromatin modifiers/remodelers, including AT-rich interactive domain 1A (ARID1A), KDM6A, CREB binding protein (CREBBP), E1A, E1A binding protein p300 (EP300), myeloid/lymphoid or mixed-lineage leukemia 1 (MLL1), MLL2, MLL3, and nuclear receptor corepressor 1 (NCOR). Recent studies have highlighted alterations in stromal antigen 2 (STAG2) and other genes involved in chromosome segregation acting as tumor suppressors [5]. The TCGA has also identified mutations in a nuclear factor, thioredoxin interacting protein (TXNIP), involved in the response to oxidative stress in 15% of tumors, which suggests putative therapeutic targets including receptor tyrosine kinases (FGFR3 and ERBB1-3) and nuclear receptors. The completion of the TCGA project and the expansion of other populations will provide a more comprehensive map of aggressive bladder tumors. Initial studies in PCa have focused on broad characterization.

The identification of complex multichromosomal genomic rearrangement loops and of recurrent speckle-type POZ protein (SPOP), forkhead box A1 (FOXA1), MLL2, and

mediator complex subunit 12 (MED12) mutations has provided new insights into PCa genetics. Subsequent work in PCa has focused on specific disease subgroups.

A sophisticated study of pretreatment metastatic PCa revealed mutational profiles comparable to the earlier stage of disease and the functional impact of FOXA1 mutations in androgen responsiveness [6]. Another focused report on 11 early-onset tumors showed the distinct, age-related, mutational profiles as well as sustained dysregulation of androgen signalling [7]. These large- scale projects will answer some fundamental questions about PCa, such as mutation-driving PCa profiles and the mutation-associated patient phenotyping.

To obtain the appropriate biological insights from NGS-based studies, a great need exists to apply rigorous bioinformatics procedures to digest the big data. Once sequencing is completed, raw sequence data must undergo multiple steps of analysis. A generalized data analysis pipeline for NGS data includes preprocessing the data to remove adapter sequences and low-quality reads, mapping of the data to a reference genome or de novo alignment of the sequence reads, and analysis of the compiled sequence.

Analysis of the sequence must include a wide variety of bioinformatics assessments, including genetic variant calling for detection of SNPs or indels (i.e., the insertion or deletion of bases), detection of novel genes or regulatory elements, and assessment of transcript expression levels.

Analysis can also include identification of both somatic and germ-line mutation events that may contribute to the diagnosis of a disease or genetic condition. Many free web-based tools and software packages are available to perform the bioinformatics analyses, which are necessary to successfully analyze the NGS data.

It is expected that the substantial power of NGS will be revealed at additional levels, including understanding tumor progression, prevention, and early detection. NGS technology is already providing new knowledge about the molecular pathogenesis of cancer. The common players involved in the major urologic cancers have likely been identified; however, the many mutations remain poorly characterized. In the next several years, more therapeutically targetable mutations will be discovered, with a scientific consideration of differences according to tumor subtype or population characteristics (e.g., gender, age, and ethnicity). The recent approval of NGS technology for clinical application by the US Food and Drug Administration sets the stage for a transformation in precision medicine.

(3)

89

Korean J Urol 2015;56:87-89. www.kjurology.org

Next generation sequencing and urologic cancer

CONFLICTS OF INTEREST

The authors have nothing to disclose.

REFERENCES

1. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al. Exome sequencing identifies frequent mutation of the SWI/

SNF complex gene PBRM1 in renal carcinoma. Nature 2011;

469:539-42.

2. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, Leng N, Pavia- Jimenez A, Wang S, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012;44:751-9.

3. Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen YB, Gonen M, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2:

a report by MSKCC and the KIRC TCGA research network.

Clin Cancer Res 2013;19:3259-67.

4. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma.

Nature 2013;499:43-9.

5. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, et al. Whole- genome and whole-exome sequencing of bladder cancer iden- tifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013;45:1459-63.

6. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration- resistant prostate cancer. Nature 2012;487:239-43.

7. Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichen- han D, Minner S, et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013;23:159-70.

참조

관련 문서

First, uniformity in the form of cooperative classes recommended by the Korea Culture, Arts and Education Promotion Agency, the main body of the support

Sequencing results of groEL gene of Anaplasma phagocytophilum detected in blood, kidney and spleen of wild rodents captured in Jeollanam-do area using a

We determined the nucleotide sequences of the mitochondrial DNA (mtDNA) control region using cloning and sequencing, and obtained the complete sequence from the cattle bones

First, as for the relationship between interest factor and self-esteem formation, human relation factor as an interest factor had a significant effect at

In this work, as the first-generation Asian American, both Moon Orchid and Brave Orchid consciously keep the traditional culture and customs as the

Full genome cloning and nucleotide sequence analysis of hepatitis C virus from sera of chronic hepatitis patients in Korea. Detection of hepatitis C virus RNA

CT26 tumor bearing mouse에 광역동치료를 시행하고 24시간 경과 후 종양 조직에서 RNA를 분리하여 mRNA-sequencing 법으로 정단부 원형질막 구성요소 관련 유전자

For confirmation of results of direct real-time melting curve analysis, we also performed an in-house JAK2 V617F ASP and a BsaXI-treated nested PCR-direct